ClinicaliQ Trial Snapshot
- A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide — Recruiting • Phase II • Diabetes / Metabolic • NCT06897475.
- What is being tested: LY3457263, a novel investigational agent, is being evaluated as an add-on therapy to semaglutide or tirzepatide in patients whose blood glucose remains inadequately controlled on these agents alone, with HbA1c reduction as the primary efficacy measure.
- Patient eligibility overview: The trial enrolls adults with type 2 diabetes currently on stable doses of semaglutide or tirzepatide who have not achieved HbA1c targets, representing a population requiring intensified glycaemic control despite GLP-1 receptor agonist or dual GLP-1/GIP agonist therapy.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.
Eligibility Snapshot
- : * Have type 2 diabetes * Have HbA1c ≥7.5% to ≤10.5% at screening * Have a body mass index (BMI) of ≥27 kilograms per square meter (kg/m2) at screening * Have had a stable body weight for the three months prior to screening * On stable treatment dose of one of the following incretins for at least three months prior to screening: * Injectable semaglutide (1 and 2 milligram (mg)) * Injectable tirzepatide (5, 7.5, 10, 12.5 and 15 mg)
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.